Beyond traditional T cells, CAR‐M and CAR‐NK serve as versatile platforms capable of infiltrating ‘immune‐cold tumors’ and mediating non‐antigen dependent phagocytosis.[164, 191] Notably, cell therapies are extending beyond oncology to address a variety of medical conditions, including autoimmune diseases exemplified by CD19‐CAR Tregs for multiple sclerosis and chronic infections represented by CCR5‐modified CAR‐T therapies targeting HIV reservoir clearance.[192] This highlights the broad applicability of cell‐type‐specific programming. The gene discussed is CCR5; the disease is multiple sclerosis.